Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carfilzomib Dose Comparison in Relapsed/Refractory Multiple Myeloma
NCT01903811Phase 2Completed
- Sponsor
- SWOG Cancer Research Network
- Start
- Oct 2013
- Primary completion
- Nov 2017
- Modality
- Irreversible Covalent Inhibitors, Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of carfilzomib in multiple myeloma (MM) (2 arms), sponsored by SWOG Cancer Research Network. Primary endpoint: Progression-free Survival at 2 years. Started Oct 2013; status: completed.
02
Drugs
carfilzomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01903811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01903811.